255 related articles for article (PubMed ID: 22951631)
1. Exposure to antiretroviral therapy and risk of cancer in HIV-infected persons.
Chao C; Leyden WA; Xu L; Horberg MA; Klein D; Towner WJ; Quesenberry CP; Abrams DI; Silverberg MJ
AIDS; 2012 Nov; 26(17):2223-31. PubMed ID: 22951631
[TBL] [Abstract][Full Text] [Related]
2. HIV infection and the risk of cancers with and without a known infectious cause.
Silverberg MJ; Chao C; Leyden WA; Xu L; Tang B; Horberg MA; Klein D; Quesenberry CP; Towner WJ; Abrams DI
AIDS; 2009 Nov; 23(17):2337-45. PubMed ID: 19741479
[TBL] [Abstract][Full Text] [Related]
3. Cancer risk and use of protease inhibitor or nonnucleoside reverse transcriptase inhibitor-based combination antiretroviral therapy: the D: A: D study.
Bruyand M; Ryom L; Shepherd L; Fatkenheuer G; Grulich A; Reiss P; de Wit S; D Arminio Monforte A; Furrer H; Pradier C; Lundgren J; Sabin C;
J Acquir Immune Defic Syndr; 2015 Apr; 68(5):568-77. PubMed ID: 25763785
[TBL] [Abstract][Full Text] [Related]
4. Incidence of non-AIDS-defining cancer in antiretroviral treatment-naïve subjects after antiretroviral treatment initiation: an ACTG longitudinal linked randomized trials analysis.
Krishnan S; Schouten JT; Jacobson DL; Benson CA; Collier AC; Koletar SL; Santana J; Sattler FR; Mitsuyasu R;
Oncology; 2011; 80(1-2):42-9. PubMed ID: 21606663
[TBL] [Abstract][Full Text] [Related]
5. Cancer, immunodeficiency and antiretroviral treatment: results from the Australian HIV Observational Database (AHOD).
Petoumenos K; van Leuwen MT; Vajdic CM; Woolley I; Chuah J; Templeton DJ; Grulich AE; Law MG;
HIV Med; 2013 Feb; 14(2):77-84. PubMed ID: 22934689
[TBL] [Abstract][Full Text] [Related]
6. Relationship of immunologic response to antiretroviral therapy with non-AIDS defining cancer incidence.
Yanik EL; Napravnik S; Cole SR; Achenbach CJ; Gopal S; Dittmer DP; Olshan AF; Kitahata MM; Mugavero MJ; Saag M; Moore RD; Mathews WC; Hunt P; Eron JJ
AIDS; 2014 Apr; 28(7):979-87. PubMed ID: 24681415
[TBL] [Abstract][Full Text] [Related]
7. Trends in the incidence of cancers among HIV-infected persons and the impact of antiretroviral therapy: a 20-year cohort study.
Crum-Cianflone N; Hullsiek KH; Marconi V; Weintrob A; Ganesan A; Barthel RV; Fraser S; Agan BK; Wegner S
AIDS; 2009 Jan; 23(1):41-50. PubMed ID: 19050385
[TBL] [Abstract][Full Text] [Related]
8. Long-term exposure to combination antiretroviral therapy and risk of death from specific causes: no evidence for any previously unidentified increased risk due to antiretroviral therapy.
Kowalska JD; Reekie J; Mocroft A; Reiss P; Ledergerber B; Gatell J; d'Arminio Monforte A; Phillips A; Lundgren JD; Kirk O;
AIDS; 2012 Jan; 26(3):315-23. PubMed ID: 22112597
[TBL] [Abstract][Full Text] [Related]
9. Incidence and risk factors for the occurrence of non-AIDS-defining cancers among human immunodeficiency virus-infected individuals.
Burgi A; Brodine S; Wegner S; Milazzo M; Wallace MR; Spooner K; Blazes DL; Agan BK; Armstrong A; Fraser S; Crum NF
Cancer; 2005 Oct; 104(7):1505-11. PubMed ID: 16104038
[TBL] [Abstract][Full Text] [Related]
10. The Association of HIV Control and Immunosuppression With Risk of Non-AIDS-Defining Cancer Risk Among Patients on Antiretroviral Therapy.
Dickey BL; Yanik EL; Thompson Z; Burkholder G; Kitahata MM; Moore RD; Jacobson J; Mathews WC; Christopoulos KA; Fleming J; Napravnik S; Achenbach C; Coghill AE
J Acquir Immune Defic Syndr; 2024 Mar; 95(3):275-282. PubMed ID: 37977197
[TBL] [Abstract][Full Text] [Related]
11. Incidence of AIDS-defining cancers and virus-related and non-virus-related non-AIDS-defining cancers among HIV-infected patients compared with the general population in a large health district of Northern Italy, 1999-2009.
Calabresi A; Ferraresi A; Festa A; Scarcella C; Donato F; Vassallo F; Limina R; Castelli F; Quiros-Roldan E;
HIV Med; 2013 Sep; 14(8):481-90. PubMed ID: 23560682
[TBL] [Abstract][Full Text] [Related]
12. Immunodeficiency and risk of myocardial infarction among HIV-positive individuals with access to care.
Silverberg MJ; Leyden WA; Xu L; Horberg MA; Chao CR; Towner WJ; Hurley LB; Quesenberry CP; Klein DB
J Acquir Immune Defic Syndr; 2014 Feb; 65(2):160-6. PubMed ID: 24442222
[TBL] [Abstract][Full Text] [Related]
13. Increased risk of non-AIDS-defining cancers in Asian HIV-infected patients: a long-term cohort study.
Nagata N; Nishijima T; Niikura R; Yokoyama T; Matsushita Y; Watanabe K; Teruya K; Kikuchi Y; Akiyama J; Yanase M; Uemura N; Oka S; Gatanaga H
BMC Cancer; 2018 Nov; 18(1):1066. PubMed ID: 30400779
[TBL] [Abstract][Full Text] [Related]
14. The effect of HIV infection, immunodeficiency, and antiretroviral therapy on the risk of hepatic dysfunction.
Towner WJ; Xu L; Leyden WA; Horberg MA; Chao CR; Tang B; Klein DB; Hurley LB; Quesenberry CP; Silverberg MJ
J Acquir Immune Defic Syndr; 2012 Jul; 60(3):321-7. PubMed ID: 22343179
[TBL] [Abstract][Full Text] [Related]
15. Cancer incidence and mortality for all causes in HIV-infected patients over a quarter century: a multicentre cohort study.
Raffetti E; Albini L; Gotti D; Segala D; Maggiolo F; di Filippo E; Saracino A; Ladisa N; Lapadula G; Fornabaio C; Castelnuovo F; Casari S; Fabbiani M; Pierotti P; Donato F; Quiros-Roldan E;
BMC Public Health; 2015 Mar; 15():235. PubMed ID: 25884678
[TBL] [Abstract][Full Text] [Related]
16. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
17. Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.
; Yeni P; Cooper DA; Aboulker JP; Babiker AG; Carey D; Darbyshire JH; Floridia M; Girard PM; Goodall RL; Hooker MH; Mijch A; Meiffredy V; Salzberger B
Lancet; 2006 Jul; 368(9532):287-98. PubMed ID: 16860698
[TBL] [Abstract][Full Text] [Related]
18. No increased risk of hepatotoxicity in long-term use of nonnucleoside reverse transcriptase inhibitors in HIV-infected patients.
Van Welzen B; Mudrikova T; Arends J; Hoepelman A
HIV Med; 2012 Aug; 13(7):448-52. PubMed ID: 22413955
[TBL] [Abstract][Full Text] [Related]
19. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
[TBL] [Abstract][Full Text] [Related]
20. Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis.
Haas AD; Keiser O; Balestre E; Brown S; Bissagnene E; Chimbetete C; Dabis F; Davies MA; Hoffmann CJ; Oyaro P; Parkes-Ratanshi R; Reynolds SJ; Sikazwe I; Wools-Kaloustian K; Zannou DM; Wandeler G; Egger M;
Lancet HIV; 2015 Jul; 2(7):e271-8. PubMed ID: 26423252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
